Takada, Ryoji
Ikezawa, Kenji
Yamai, Takuo
Watsuji, Ko
Seiki, Yusuke
Kawamoto, Yasuharu
Hirao, Takeru
Higashi, Sena
Urabe, Makiko
Kai, Yugo
Nakabori, Tasuku
Uehara, Hiroyuki
Kotani, Michiyo
Yagi, Toshinari
Kimura, Miho
Nozaki, Keisuke
Takagi, Mari
Ohkawa, Kazuyoshi
Article History
Received: 21 April 2023
Accepted: 21 July 2023
First Online: 31 July 2023
Declarations
:
: This study was approved by the Institutional Regimen Committee and Institutional Review Board of Osaka International Cancer Institute (22004–4) and was conducted in accordance with the Declaration of Helsinki. The requirement for informed consent was waived owing to the retrospective nature of this study. A waiver of informed consent was granted by the Institutional Review Board of Osaka International Cancer Institute.
: Not applicable.
: Takada reports honoraria for lectures from Hisamitsu Pharmaceutical, Novartis, and TEIJIN PHARMA. Ikezawa reports honoraria for lectures from Taiho Pharmaceutical, Yakult Honsha, Ono Pharmaceutical, MSD, Myriad Genetics, ASAHI KASEI PHARMA, and Incyte Biosciences Japan, and research funding from ASKA Pharmaceutical. Yamai reports honoraria for lectures from Taiho Pharmaceutical and Yakult Honsha. Yagi reports honoraria for lectures from Eisai and Becton Dickinson Japan. Ohkawa reports honoraria for lectures from Eisai, Chugai Pharmaceutical, Yakult Honsha, Incyte Biosciences Japan, Takeda, Gilead and Hisamitsu, and research grants from Towa Pharmaceutical and Sumitomo Chemical. The other authors have no conflict of interest.